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1 Drug description 
Generic/Brand name/ATC code:  
Ipilimumab, MDX-010, MDX-101/Yervoy®/ L01XC11 
Developer/Company:  
Bristol-Myers-Squibb and Medarex 
Description:  
Ipilimumab is a fully human monoclonal antibody directed against the cyto-
toxic T-lymphocyte antigen 4 (CTLA-4), an antigen which is expressed on 
T-cells only after activation [1]. CTLA-4 down-regulates T-cell mediated 
immune responses. By blocking this antigen, T-cell suppression is reduced 
and thus an anti-tumour immune response enhanced [2, 3].  
Due to its mode of action, a novel set of side-effects, the so called “immune-
related adverse events” (irAEs) are related to anti-CTLA4 antibodies [4]. 
These AEs are associated with breaking the tolerance to self-antigens and 
are dose-related, cumulative and schedule dependent [3]. A relationship be-
tween occurrence of these side-effects and anti-tumour activity is being dis-
cussed [3, 4].   
Ipilimumab is administered intravenously. Frequently used regimens were 
induction therapy with either 3mg/kg or 10mg/kg every three weeks over 12 
weeks, followed by maintenance therapy, mostly 10mg/kg every 12 weeks 
[3]. However, in Europe the licensed dose is 3mg/kg every 3 weeks for a total 
of four doses [5].  
2 Indication  
Ipilimumab is indicated for the first-line therapy of patients with advanced/ 
metastatic cutaneous melanoma. 
3 Current regulatory status 
In Europe, ipilimumab is licensed for  
 adults with melanoma who have been previously treated, but for 
whom treatment has not worked or has stopped working since July 
2011. The approved dose is 3 mg/kg ipilimumab intravenously every 3 
weeks for a total of four doses [5]. 
In the US, ipilimumab has orphan drug status and is licensed for: 
 the treatment of unresectable or metastatic melanoma. The recom-
mended dosage is 3mg/kg every 3 weeks for a total of four doses. [6].  
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4 Burden of disease 
Melanomas are malignant tumours of melanocytes. Suspicious lesions are 
nevi (i.e. moles or birthmarks) with, for example, variable discoloration, 
growth or development of satellites [7]. The "ABCD" method of identifica-
tion, originally described by Friedman et al. [8], has been a useful tool in fa-
cilitating the diagnosis of malignant melanoma. This method analyses four 
clinical characteristics to identify melanoma: asymmetry, border irregular-
ity, colour variegation, and a diameter of 6 mm or more.  
Risk factors for developing melanomas include prior melanomas, a positive 
family history, skin phototype and multiple clinically atypical 
moles/dysplastic nevi. In addition, genetic factors and sun exposure can con-
tribute towards the development of melanomas [9]. To confirm the diagnosis 
of melanoma a biopsy, at best by local excision, should be performed [7]. 
Several parameters of prognostic value should be considered in the histopa-
thological report on “microstaging” of the disease. The microstaging is based 
on the histologic examination of the vertical thickness of the lesion, which is 
expressed in millimetres (Breslow classification) and/or on the anatomic 
level of local invasion (Clark classification). Due to its reproducibility and 
its capability in accurately predicting the evolution of malignant melanoma 
with lesions thicker than 1.5 mm, the Breslow thickness should always be 
reported. Accurate microstaging of the primary tumour requires careful his-
tologic evaluation of the entire specimen by an experienced pathologist [10].  
 
Staging of melanomas based on the tumour, node, metastasis (TNM) system 
includes describing the spread, aggressiveness and the size of the tumour. By 
taking into account characteristics like thickness, ulcerations and the mi-
totic rate of the primary tumour, by assessing the spread to regional lymph-
nodes including satellite lesions (tumour cells separated from the primary 
tumour) and in-transit metastases and by evaluating distant metastases, pa-
tients are grouped into four prognostic categories (stage I –IV) [11]. Other 
factors which influence prognosis are gender, age and localisation of the tu-
mour where younger patients, women and patients with tumours on the ex-
tremities have a better prognosis [7]. For patients suffering from stage IV 
disease, sites of metastases and elevated lactate-dehydrogenase (LDH) levels 
are also associated with poor outcomes [9]. If the tumour has spread beyond 
near-by lymph-nodes, it is called advanced or metastatic melanoma which 
corresponds to stage IV disease. Metastases most often occur in the skin or 
in lymph-nodes, or in organs such as the lungs, the liver, the brain and in 
the bones, but also gastrointestinal secondary involvement is not rare in dis-
seminated disease. Staging is also an important factor for the determination 
of the most appropriate treatment [11].  
Median age at diagnosis of malignant melanoma is 59 years [7]. The major-
ity of patients, about 85%, present with localised disease, corresponding to 
5-year survival rates of up to 90%. In about 13% the regional lymph nodes 
are affected at diagnosis, leading to diminished survival rates of 20%-70%. 
About 2%-5% of patients present with distant metastases that is stage IV. 
Long-term survival of all patients with distant metastases is less than 10% 
[9]. Median survival is 6 to 9 months [12]. 
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Malignant melanoma accounts for 2-3% of all malignant tumours in North-
Europe and USA; incidence is rising, with an increase of 4% per year in the 
USA. In 2008, the EU incidence rate (per 100,000) of skin melanoma was 
10.0, being 9.5 among males and 10.4 among females (overall cumulative 
risk of 0.93%). Mortality rate (per 100,000) was 2.4, being 2.6 among males 
and 2.1 among females [13]. In Austria, the incidence of melanomas is about 
15 newly diagnosed cases/100,000 persons per year and is constantly rising 
[14]. In 2007, overall 1,300 people were newly diagnosed with malignant 
melanoma in Austria. Of these, about 5% of the tumours were already dis-
seminated, resulting in about 65 persons with advanced melanoma per year 
[12]. 
5 Current treatment 
Treatment of un-resectable stage III melanoma and of stage IV melanomas 
focuses on symptom palliation, on preventing the tumour to spread, to re-
duce or getting rid of metastases and to maintain or achieve an acceptable 
quality-of-life [9]. Thus, cure is rarely possible [11].  
Little consensus on the standard of care exists and enrolment onto clinical 
trials is highly recommended. Therapy may involve: 
 Surgical excision is the primary treatment for early stage melanomas, 
but is also indicated for metastatic melanoma. Resection should be 
performed for limited metastatic melanoma (i.e. if the disease has 
spread only to one site or only to a limited number of sites). If the tu-
mour has spread to multiple sites such as the brain, the lungs, gastro-
intestinal tract or lymph-nodes, surgery may be used for symptom 
palliation.   
 Single-agent chemotherapy:  
 dacarbazine (DTIC), which is licensed for melanoma in Austria, is 
currently the most active chemotherapy and has often been used as 
standard comparator for new therapeutic regimens [9]. However, 
only 10%-20% of patients respond to this treatment, showing main-
ly partial remissions with a median response duration of 3-4 
months [9]. 
 fotemustine for the treatment of disseminated malignant mela-
noma, foremost if the tumour has spread to the brain [15]. 
 temozolomide (off-label) shows similar benefits like DTIC. Due to 
its ability to penetrate into the brain and other parts of the nervous 
system, it is often used for the treatment of patients with brain me-
tastases [11]. 
 Immunotherapy:  
 high-dose interleukin-2 (licensed in the US) has shown long-lasting 
effects including complete remissions, but only in the minority of 
patients. Because of its serious side-effects, it remains a treatment 
option for patients in good condition. 
 interferon-α is licensed for the adjuvant therapy of patients who are 
disease-free after surgery but who are at high risk of systemic re-
currence [11]. 
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advanced melanoma in 
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cure rarely possible   
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 ipilimumab is approved for the second-line therapy of advanced 
melanoma. Some guidelines recommend it for patients without 
V600 mutation in BRAF who will not be treated with interleukin-2 
[9]. 
 Signal transduction inhibitors: 
 mono-therapy with vemurafenib a BRAF inhibitor is licensed for 
adult patients with BRAF V600 mutation-positive unresectable or 
metastatic melanoma in Europe since February 2012 [11, 16] . 
 Radiation therapy either to metastases outside the brain for symptom 
palliation or as whole brain radiation therapy which can prolong sur-
vival in selected cases, especially if the tumour outside the brain is 
controlled [11]. 
 Multi-agent chemotherapy and bio-chemotherapy  
 The medical literature reports numerous phase II and III trials 
employing various drug combinations. Clear evidence of the supe-
riority of multi-agent chemotherapy is still lacking, while combina-
tion therapies have shown greater toxicity [17].  
 Several studies on bio-chemotherapy have been conducted. The re-
sults of a meta-analysis show that bio-chemotherapy improves re-
sponse rates compared with chemotherapy. However, these regi-
mens were associated with an increase in haematologic toxicity 
without significant improvement in survival [18].  
Recommendations differ to some extent which of these treatment options 
should be used first [7, 9, 19]. To conclude, no standard therapy exists for 
the treatment of metastatic melanoma, but dacarbazine is at least considered 
as reference drug, even though its impact on overall survival is limited. 
Thus, inclusion into a clinical trial is highly recommended [7, 20, 21].  
6 Evidence 
Based on a literature search (15th of May 2012) in Medline, EMBASE, DARE 
(Database of the Centre for Review Dissemination of the National Institute 
of Health) and Cochrane Central, 390 references were identified overall. Of 
these, 1 phase III [22] and 1 phase II trial [23] were included. 1 study which 
had included both previously treated as well as untreated patients was ex-
cluded because no separate results were provided for previously untreated 
patients [24]. However, a retrospective analysis of this primary study pro-
vides results for the first-line therapy only and was therefore included [25].  
 
and radiation therapy   
 
or clinical trials  
 
1 phase III,  
1  phase II trial  
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6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy 
Study title  
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma [22, 26] 
Study  
identifier 
Clinical trial identifier: NCT00324155, EUDRACT Number 2005-006082-14, Protocol 
Number: CA184-024 
Multinational, randomized, double-blind, placebo controlled phase 3 study Design 
Duration  Enrolment: August 2006 - January 2008 
Median follow-up: 54 months 
Cut-off date for final analysis: February 2013 
Hypothesis Superiority 
Among patients with previously untreated Stage IIIc, N3 (unresectable) or Stage IV 
melanoma (American Joint Committee on Cancer 2001 and measurable per modified 
World Health Organization [WHO] criteria), overall survival (OS) in patients receiving 
dacarbazine plus 10 mg/kg ipilimumab will be superior to that in patients receiving 
dacarbazine with placebo. 
Funding Bristol-Myers Squibb 
Intervention 
(n= 250) 
Induction phase: Ipilimumab (10 mg/kg) plus dacarbazine (850 
mg/m2) at weeks 1, 4, 7, and 10, followed by dacarbazine alone eve-
ry 3 weeks through week 22  
Maintenance phase: from week 24, patients with stable disease or 
an objective response during the induction phase who did not have 
a dose-limiting adverse event received ipilimumab every 12 weeks 
until progression of the disease, development of toxic effects, or the 
end of the study. 
Treatment 
groups 
Control 
(n= 252) 
Induction phase: Dacarbazine (850 mg/m2) plus placebo at weeks 1, 
4, 7, and 10, followed by dacarbazine alone every 3 weeks through 
week 22  
Maintenance phase: after week 24, patients with stable disease or 
an objective response during the induction phase who did not have 
a dose-limiting adverse event received placebo every 12 weeks until 
progression of the disease, development of toxic effects, or the end 
of the study. 
Overall survival  
(primary outcome) 
OS time between randomization date and death. 
Progression- 
free survival 
PFS time between randomization date and the date of progres-
sion or death, whichever occurs first. 
Best overall  
response rate 
BORR total number of randomized patients in the arm whose BOR 
is CR or PR, divided by the total number of randomized pa-
tients in the arm. 
Endpoints and 
definitions 
Disease control 
rate 
 
DCR total number of randomized patients in the arm with BOR 
of CR, PR or SD, divided by the total number of randomized 
patients in the arm. 
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Time to response - time from randomization date until measurement criteria 
are first met for overall response of PR or CR (whichever 
status is recorded first, and if subsequently confirmed). 
Duration of the re-
sponse 
- time between the date measurement criteria are first met 
for overall response of PR or CR (whichever status is re-
corded first, and if subsequently confirmed) and the date of 
disease progression or death, whichever occurs first. 
Results and analysis 
Analysis  
description 
Target number of events for the primary analysis was 416 deaths, which was estimated 
to give the study approximately 90% power to detect a 37% increase in median overall 
survival to 11 months with ipilimumab plus dacarbazine, with a corresponding hazard ra-
tio for death of 0.727, assuming a total sample of 500 patients (250 randomly assigned 
to each group) and a median survival of 8 months for the patients receiving dacarbazine 
plus placebo. 
For the analysis of overall survival, a log-rank test was performed, at a two-sided alpha 
level of 0.05, stratified according to metastasis stage (M0, M1a, M1b, or M1c) and ECOG 
performance status (0 or 1), as classified at the time of randomization. 
intention- to-treat population 
Inclusion ≥18 years, previously untreated stage III (unresectable) or stage 
IV melanoma (prior adjuvant therapy permitted) with measur-
able lesions,  ECOG PS ≤1, life expectancy ≥ 16 weeks  
Exclusion prior treatment for metastatic disease; concomitant treatment 
with immunosuppressive agents or long-term use of systemic 
glucocorticoids (except for the management of adverse events 
during the course of the study) was not allowed, brain metasta-
sis (as confirmed on imaging), primary ocular or mucosal mela-
noma, or autoimmune disease 
Analysis  
population 
Characteristics Mean age (years): I 57.5 vs. C 56.4 
Sex (%): males I 60.8 vs. C 59.1, females: I 39.2 vs. C 40.9 
ECOG-PS (%): 0: I 70.8 vs. C 71.0, 1: I 29.2 vs. C 29.0 
Metastasis stage (%): M0: I 2.4 vs. C 3.2, M1a: I 14.8 vs. C 17.1, 
M1b: I 25.6 vs. C 24.6, M1c: I 57.2 vs. C 55.2 
LDH (%): <upper limit of normal range: I 62.8% vs. 55.6%, > 
upper limit of normal range: I 37.2% vs. C 43.7% 
Prior adjuvant therapy (%): I 26 vs. C 27 
Treatment group Ipilimumab + dacarbazine  Placebo +  dacarbazine 
Number of subjects N= 250 n= 252 
OS (months)  
Median 
95%CI  
 
11.2 
9.4 – 13.6 
 
9.1 
7.8 – 10.5 
Survival rate (%) 
At 1 year (95%CI) 
At 2 years (95%CI) 
At 3 years (95%CI) 
 
47.3 (41.0–53.6) 
28.5 (22.9–34.2) 
20.8 (15.7–26.1) 
 
36.3 (30.4–42.4) 
17.9 (13.3–22.8) 
12.2 (8.2–16.5) 
Descriptive sta-
tistics and esti-
mated variabil-
ity 
 
 
 
 
 
PFS (months) 
Median 
95%CI 
 
NA 
NA 
 
NA 
NA 
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BORR (number (%)) 
CR 
PR 
SD 
PD 
Not evaluated 
38 (15.2) 
4 (1.6) 
34 (13.6) 
45 (18.0) 
111 (44.4) 
56 (22.4) 
26 (10.3) 
2 (0.8) 
24 (9.5) 
50 (19.8) 
131 (52.0) 
45 (17.9) 
DCR (%) 33.2 30.2 
Time to response NA NA 
Duration of response 
(months) 
Median  
95% CI 
 
 
19.3* 
12.1 to 26.1 
 
 
8.1 
5.19 to 19.8 
Comparison groups  Intervention vs Control 
HR 0.72 
95%CI 0.59–0.87 
OS 
P value  <0.001 
HR 0.76 
95%CI 0.63–0.93 
Progression 
P value  0.006 
DCR P value 0.41 
Effect estimate 
per comparison 
BORR P value  0.09 
Notes In an amendment approved by the Food and Drug Administration on October 9, 2008, 
the primary end point was changed from PFS to OS before the treatment assignments 
were revealed. 
*p=0.03 
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Table 2: most frequent adverse events 
Grade (according to 
CTC 3.0) 
Outcome (%) Ipilimumab + da-
carbazine 
 (n= 247) 
Placebo +  dacarba-
zine 
  (n=251) 
Adverse events regardless of cause 
Any event 244 (98.8) 236 (94.0) 
Diarrhoea 90 (36.4) 62 (24.7) 
Increase in alanine aminotransferase 82 (33.2) 14 (5.6) 
All grades (in more 
than 30% in either 
group) 
Pyrexia 91 (36.8) 23 (9.2) 
Any event 99 (40.1) 45 (17.9) 
Increase in alanine aminotransferase 40 (16.2) 2 (0.8) 
Grade 3 (in more than 
10% in either group 
Increase in aspartate aminotransferase 36 (14.6) 3 (1.2) 
Any event 40 (16.2) 24 (9.6) Grade 4 (in more than 
5% in either group) 
Increase in alanine aminotransferase 14 (5.7) 0 
Grade 5 Drug-related death 0 1 (<1) 
Immune-related adverse events 
Any event 192 (77.7) 96 (38.2) All grades (in more 
than 30% in either 
group) Diarrhoea 81 (32.8) 40 (15.9) 
Any event 78 (31.6) 8 (3.2) 
Increase in alanine aminotransferase 37 (15.0) 2 (0.8) 
Grade 3 (in more than 
10% in either group 
Increase in aspartate aminotransferase 34 (13.8) 1 (0.4) 
Any event 25 (10.1) 7 (2.8) Grade 4 (in more than 
5% in either group) 
Increase in alanine aminotransferase 14 (5.7) 0 
 
In this double-blind phase III trial, 502 patients with previously untreated 
metastatic melanoma were allocated to either ipilimumab + dacarbazine or 
to placebo + dacarbazine, followed by dacarbazine every 3 weeks (induction 
phase). Patients were about 57 years old and had in the majority ECOG-PS 
0. Approximately 55% of patients had stage M1c disease. If patients had sta-
ble disease or an objective response at 24 weeks without dose-limiting AEs, 
they could enter a maintenance phase consisting either of placebo or ipili-
mumab every 12 weeks until disease progression, development of toxic ef-
fects, or the end of the study. 
 
phase III trial 
investigated ipilimumab 
at a dose of 10mg/kg + 
dacarbazine vs placebo 
+ dacarbazine in the 1st-
line setting 
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37% of patients allocated to the ipilimumab + dacarbazine group received 
all planned four doses of the induction therapy in comparison to 66% in the 
placebo +dacarbazine group. The corresponding numbers of patients receiv-
ing at least one maintenance dose were 17% in the ipilimumab + dacarba-
zine group and 21% in the placebo + dacarbazine group. Even though the 
most common reason for treatment discontinuation was progressive disease 
(I 46% vs C 77%), considerably more patients stopped treatment due to 
drug-related AEs in the ipilimumab + dacarbazine group (36.0%) than in 
the placebo + dacarbazine group (4.0%). Of these patients, 34% in the 
ipilimumab + dacarbazine group and 4.0% in the placebo + dacarbazine 
group discontinued due to a drug-related AE during the induction phase.  
After disease progression, 55% of the patients in the ipilimumab + dacarba-
zine group and 59% in the placebo + dacarbazine group received subse-
quent therapy, consisting of chemotherapy (I 38% vs C 35%) or immuno-
therapy (2% in each group).  
Median overall survival (OS), the primary outcome, was 11.2 months 
(95%CI 9.4 to 13.6) in the ipilimumab + dacarbazine group and 9.1 months 
(95% CI 7.8 to 10.5) in the control group, yielding a hazard ratio of 0.72 
(p<0.001). Survival rates at 1, 2 and 3 years were 47.3%, 28.5% and 20.8% in 
the ipilimumab + dacarbazine group and 36.3%, 17.9% and 12.2% in the 
control group respectively. Median progression-free survival (PFS) was simi-
lar in the two groups, but since differences occurred later on (that is after 
week 12) a 24% reduction in the risk of progression was statistically signifi-
cant. In contrast, disease control rates as well as best overall response were 
comparable. Of these, complete responses were observed rarely in both 
groups (ipilimumab + dacarbazine 1.6% vs placebo + dacarbazine 0.8%) 
and partial responses occurred in 13.6% in the ipilimumab + dacarbazine 
group and in 9.5% in the placebo +dacarbazine group. Amongst these pa-
tients, median duration of response was 19.3 months in the ipilimumab + 
dacarbazine group in comparison to only 8.1 months in the placebo + 
dacarbazine group (p = 0.03), but the limited number of observed events 
suggests, that these data should be carefully interpreted. Outcomes associ-
ated with quality-of-life were not evaluated. 
Overall, AEs were very frequent in both groups, but those of higher grades 
were more often observed in the ipilimumab + dacarbazine group. Grade 3 
or 4 AEs were seen in 56% of patients receiving ipilimumab + dacarbazine 
and in 28% of patients receiving placebo + dacarbazine (p<0.001). Of these, 
40% were of grade 3 and 16% of grade 4 in the ipilimumab + dacarbazine 
group in comparison to 18% and 10% in the placebo + dacarbazine group. 
An additional safety analyses, concerning immune-related AEs was also per-
formed, which were the most frequent study-drug related AEs (Overall: 
ipilimumab + dacarbazine 78% vs placebo + dacarbazine 38%). More se-
vere immune-related AEs (i.e. grade ≥3) occurred in 38% in the ipilimumab 
+ dacarbazine group and in 4% in the placebo group. The most common 
ones in the ipilimumab group were liver-associated AEs such as increase in 
liver enzymes and hepatitis (see table 2). AEs were also more frequent in the 
ipilimumab + dacarbazine group during the maintenance phase, but the 
most common ones of all grades were rash (I 26% vs C 6%), pruritus (I 16% 
vs C 4%) or diarrhoea (ipilimumab + dacarbazine 14% vs placebo + dacar-
bazine 6%).  
overall 502 patients 
 
more patients 
discontinued ipilimumab 
therapy than in the 
control arm 
 
only 37% of pts received 
all planned 4 doses 
median OS: +2.1 months 
for the ipilimumab 
group 
 
similar results for 
disease control rates and 
for overall low response 
rates 
 
but: duration of 
response longer in the 
ipilimumab group 
AEs, also of higher 
grade, more frequent in 
the combination arm 
grade 3+4 in 56% of pts 
in ipilimumab arm vs 
28% in dacarbazine only 
arm 
 
foremost immune-
related AEs  
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6.2 Efficacy and safety - further studies 
An open-label, randomised phase II trial [23] investigated ipilimumab with 
or without dacarbazine in chemotherapy-naïve patients. Overall 72 patients 
were assigned to either of the groups. Treatment with ipilimumab consisted 
of 3mg/kg every 4 weeks for four doses and dacarbazine was administered at 
250mg/m² for five consecutive days every 3 weeks. 13 patients (of 37) ini-
tially assigned to ipilimumab only crossed over to ipilimumab + dacarba-
zine after disease progression. Like in the phase III trial, only the minority 
of patients (i.e. 30% in the mono-therapy arm and 46% in the combination 
arm) finished a full treatment course. Best objective response rate, the pri-
mary efficacy outcome, was 5.4% in the ipilimumab only group and 14.3% 
in the combination arm; in the ipilimumab only group all responses were 
partial responses, whereas the combination of ipilimumab + dacarbazine 
yielded in 5.7% complete responses and in 8.6% partial responses. At me-
dian follow-up (ipilimumab only: 16.4 months, ipilimumab + dacarbazine: 
20.9 months), median OS was 11.4 months in the ipilimumab arm and 14.3 
months in the combination arm. The corresponding 12-, 24 and 26-month 
survival rates were 45%, 21% and 9% in the ipilimumab alone group and 
62%, 24% and 20% in the ipilimumab + dacarbazine group. Treatment-
related AEs (safety population comprised 74 patients) of grade ≥3 were 
more frequent in the combination arm (23%) than in the single-drug group 
(13%). Immune-related AEs of any grade were observed in 54% (8% severe 
AEs, 10% serious AEs) in the ipilimumab only group and in 66% in the 
ipilimumab + dacarbazine group (17% severe AEs, 14% serious AEs). In 
each group, 1 patient had died; the death in the ipilimumab group was con-
sidered as related to therapy and that in the combination arm was consid-
ered possibly related to treatment.  
A retrospective analysis of a phase II study which had enrolled treated as 
well as untreated patients, provides separate results for each of these groups 
[25]. The primary objective of the initial study [24] was to investigate 
whether addition of budesonide to ipilimumab reduced the rates of grade 
≥2 diarrhoea in comparison to placebo. The retrospective analysis com-
prised 115 patients in total of which 53 were treatment-naïve. For these pa-
tients, median OS was 30.5 years and the 1-year survival rate was 69.4%. At a 
median follow-up of 18.5 months, the disease control rate (35.8%) and the 
best overall response rate (13.2%) were similar to the phase III study. Rates 
of grade ≥2 diarrhoea were 31.3% with placebo and 38.1% with budesonide 
and grade ≥2 diarrhoea or colitis were 31.3% with placebo and 47.6% with 
budesonide.  
These safety data confirm those seen in the study on 676 pre-treated pa-
tients, submitted to obtain the authorisation of ipilimumab as second-line 
therapy in the EU [27].  
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7 Estimated costs 
Cost estimates for ipilimumab range from € 16,660.- to € 20,893.- for one 40 
ml vial a 5mg/ml Yervoy® containing 200mg and from € 4,250.- to € 5,266.- 
for one 10 ml vial containing 50mg ipilimumab [28, 29].  
Even though the licensed dosage is 3mg/kg (in the U.S. this dosage is also 
used for the first-line setting) 10mg/kg ipilimumab were administered in the 
phase III trial. Assuming an average body weight of 70 kg and a therapy with 
3 mg/kg, the costs for one infusion with ipilimumab would range from € 
20,825.- to € 26,116.- (= 1x200mg vial + 1x50mg vial). Total treatment costs 
for induction therapy consisting of four cycles of ipilimumab add therefore 
up to € 83,300.- and € 104,465.-.  
If 10 mg/kg were used instead, costs would increase considerably. One 
course would then be € 58,310.- or € 73.126.- (= 3x200mg vials + 2x50mg vi-
als), resulting in total cost of € 233,240.- or € 292,502.- for four cycles. 
8 On-going research 
No on-going phase III studies were found for the indication investigated on 
www.clinicaltrials.gov or on www.clinicaltrialsregister.eu/ctr-search, but two 
trials assessing the efficacy of ipilimumab after complete resection of ad-
vanced melanoma are on-going. Furthermore, other indications currently 
tested in phase III are small cell lung cancer and prostate cancer.  
Ipilimumab is under investigation in phase II trials for other cancer types 
including ovarian cancer, pancreatic cancer and non-small cell lung cancer.  
9 Commentary  
Ipilimumab is licensed only for pre-treated patients in Europe [5]. In the 
U.S., the drug was approved for both previously treated as well as untreated 
patients. FDA’s decision to also include first-line therapy rested upon the 
fact that they had already top line OS results of the phase III study con-
ducted in the first line setting [30].  
cost estimates depend 
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10mg/kg for one 
treatment cycle   
resulting in € 83,300.- - 
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This phase III trial compared ipilimumab + dacarbazine to placebo + 
dacarbazine in previously untreated patients. Even though dacarbazine is 
the reference drug currently, its own activity for the treatment of melanoma 
is limited. However, OS was significantly longer in the ipilimumab group, 
but the gain was with 2.1 months rather modest. Moreover, although dura-
tion of response was considerably longer in the combination arm than in the 
control arm, responses occurred in both groups only in a minority of pa-
tients and were not statistically significant in between the two groups (ipili-
mumab + dacarbazine: 15% vs placebo + dacarbazine: 10%).  
The incidence of grade 3 or grade 4 AEs, foremost driven by immune-related 
AEs, was also higher in the combination arm than in the dacarbazine + pla-
cebo group. Subsequently, considerably more patients stopped treatment 
due to drug-related AEs in the ipilimumab + dacarbazine group (36%) than 
in the placebo + dacarbazine group (4%), resulting in only 37% who re-
ceived all four doses of the induction therapy in the ipilimumab + dacarba-
zine group in comparison to 66% in the placebo + dacarbazine group. Fur-
thermore, the kind of AEs did not match those observed in previous studies 
since hepatic toxicity was more frequent and other immune related toxicities 
(e.g. colitis, rash, hypophysitis) were less frequent [11, 31]. Unfortunately, 
outcomes associated with quality-of-life were not reported. One explanation 
might be that the immune toxicity profile of ipilimumab was altered by the 
addition of dacarbazine, a fact potentially associated with a change in the 
anti-tumour effect too [11]. 
Besides the fact that it remains unclear why ipilimumab was tested in com-
bination with dacarbazine and not alone, it is doubtful that combining these 
two agents offers advantages beyond single-agent therapy [11, 19, 31]. In the 
light of low response rates other combinations are being explored to increase 
activity of ipilimumab, for example, in combination with bevacizumab, IL-2 
or vemurafenib [19, 32]. Other ways which are discussed currently and 
which may increase the efficacy of ipilimumab are determination of factors 
which allow selection of patients and identification of predictive variables 
for treatment response [32]. Some authors mention molecular status [32] or 
baseline inducible co-stimulatory molecule T-cells as a potential options, 
but until now no reliable predictors of response to this immuno-therapy ex-
ist [19].  
 
Another open question concerns comparative efficacy data of ipilimumab 
and other available treatment options for the first-line therapy such as IL-2 
or vemurafenib. Yet, the optimal sequencing and timing of different thera-
pies in the first-line setting remains undefined [6]. Even though some rec-
ommendations indicate that IL-2 should be preferred if patients are able to 
tolerate this rather toxic therapy, vemurafenib should be restricted to pa-
tients with certain mutations (V600 mutation in BRAF), whereas ipilimu-
mab can be considered in patients without these mutations and who are not 
eligible for IL-2 [11, 33]. This reasoning is caused by the mode of action of 
ipilimumab. Due to its impact on the immune system, immune cells infil-
trate the tumour, cause swelling and therefore increase tumour-related 
symptoms initially. Thus, ipilimumab therapy might not be indicated in pa-
tients with a high disease burden but preferably in asymptomatic, oligome-
tastatic subjects [31]. The initial swelling has also led to calls for new crite-
ria, besides the commonly used RECIST criteria, since response to ipilimu-
mab may be mistaken as disease progression. 
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Comparative data become even more important since several new drugs for 
the first-line therapy of melanoma are in advanced phases of clinical devel-
opment. For example, trametinib, an oral selective MEK inhibitor demon-
strated in a phase III trial improvements in PFS (primary endpoint) in 
comparison to dacarbazine + paclitaxel (4.8 vs 1.4 months). Other agents 
under development are, for example, albumin-bound paclitaxel 
(NCT00864253: primary results anticipated in July 2012),  masitinib 
(NCT01280565: primary results anticipated in December 2013) or talimo-
gene laherparepvec (NCT00769704: primary results anticipated in 2012).  
A further important point concerns the optimal dosing of ipilimumab. The 
approved dose of ipilimumab is 3mg/kg but 10mg/kg were used in the phase 
III trial, a regimen being also used in on-going phase III trials.  Although 
the two different regimens will be compared in a phase III trial 
(NCT01515189) its results cannot be expected prior to 2017. In addition to 
consequences for efficacy, the impact of the two dosing regimens on treat-
ment costs cannot be neglected. Estimates indicate that cost differences of 
nearly € 170,000.- over a course of four cycles might incur, not taking any ex-
tra costs for maintenance therapy into account.  
Despite advances in the development of novel treatment strategies for ad-
vanced melanoma, a gain of only 2.1 months in OS with a considerable in-
crease in toxicities and at high costs might not justify ipilimumab therapy 
currently. Further selection criteria may improve the potential to benefit, 
but as long as more convincing data are missing, enrolment in clinical trials 
is still indicated.  
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